Cargando…
Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities
Developing drugs that target KRAS, the most frequently mutated oncogene in cancer, has not been successful despite much concerted efforts dedicated towards it in the last thirty years. Considering the key role this driver oncogene plays, the pharmacological drugging of KRAS remains a key challenge f...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5850913/ https://www.ncbi.nlm.nih.gov/pubmed/29534749 http://dx.doi.org/10.1186/s13046-018-0719-1 |